Samsung Bioepis is lined up to copy 9 of the blockbuster drugs on this tracker, which earned $79.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Samsung Bioepis's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Pyzchiva |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Ospomyv |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Xbryk |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Enbrel Eticovo |
Amgen | Biosimilar | 2029 | FDA-approved, Apr 2019; blocked until 2029 | $2.2B |
| Entyvio | Takeda | Biosimilar | 2032 | Early development (announced Jan 2026) | ≈$6.0B |
| Keytruda SB27 |
Merck | Biosimilar | 2028 | Phase 3 complete; filed in Korea, Aug 2026 | $31.7B |
| Taltz SB35 |
Eli Lilly | Biosimilar | 2030 | Phase 1 started Aug 2026 | $3.6B |
| Dupixent | Sanofi / Regeneron | Biosimilar | 2031 | Early development | $17.8B |
| Tremfya | Johnson & Johnson | Biosimilar | 2031 | Early development | $5.2B |
Company facts: Business Wire. Each drug page lists sources for these entries. Brand sales show the size of the market, not Samsung Bioepis's share of it.